Onconova Therapeutics, Inc. Warrants
ONTXW
ONTXW was delisted on the 23rd of July, 2021.
4 hedge funds and large institutions have $15K invested in Onconova Therapeutics, Inc. Warrants in 2020 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and closing their positions.
400% more capital invested
Capital invested by funds: $3K → $15K (+$12K)
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.97K |
| 2 |
VF
Virtu Financial
New York
|
+$2.15K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$193 |
ONTXW Hedge Fund Activity: Q4 2020 in Review
4 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Onconova Therapeutics, Inc. Warrants (ONTXW) for Q4 2020, worth a combined $15K — up 400% from $3K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ONTXW positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Susquehanna International Group, adding an estimated $2.97K. The largest seller was Citadel Advisors, cutting an estimated $193.
- 4 institutional investors held Onconova Therapeutics, Inc. Warrants (ONTXW) as of Q4 2020, up from 3 in Q3 2020.
- Funds reported $15K of Onconova Therapeutics, Inc. Warrants stock for Q4 2020, up 400% quarter-over-quarter.
- 1 fund opened new Onconova Therapeutics, Inc. Warrants positions in Q4 2020 and 0 closed out, a net change of +1 holder.
- The largest Onconova Therapeutics, Inc. Warrants buyer in Q4 2020 was Susquehanna International Group, an estimated $2.97K added.
- The largest Onconova Therapeutics, Inc. Warrants seller in Q4 2020 was Citadel Advisors, an estimated $193 sold.
Based on aggregated 13F filings for Q4 2020.